Geneva, Switzerland, 04 November 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…
Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
8th Annual Sofinnova Japan Biopharma Partnering Conference – Tokyo, Japan
15th Annual Biotech in Europe Forum – Basel, Switzerland
ObsEva Appoints Elke Bestel as Chief Medical Officer and Jean-Pierre Gotteland as Chief Scientific Officer
Geneva, Switzerland, 22 September 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…
ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also Preterm Labor Related Inflammation Pathways
01 Sep 2015 Geneva, Switzerland, 01 September 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs…
ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study – Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women –
Geneva, Switzerland, 23 June 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…
BIO-Europe Spring 2015® – Paris, France
ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour – Positive Safety, Rapid Absorption and Absence of Interaction with Betamethasone is Basis for Phase 2 Study –
Geneva, Switzerland, 26 February 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…
ObsEva Announces the Initiation of a Pivotal Phase 2 Study to Evaluate OBE001 for Improving Embryo Implantation and Clinical Pregnancy Rate in Women Undergoing IVF/ICSI
Geneva, Switzerland, 18 November 2014 – ObsEva, a Swiss biopharmaceutical company dedicated to the development and commercialization of innovative drugs…
ObsEva SA appoints Ben T.G. Tan as VP Commercial & Business Development
Geneva, Switzerland, 10 September 2014 – ObsEva, a Swiss-based, specialty biopharmaceutical company dedicated to the development and commercialisation of innovative…